| Name | Title | Contact Details |
|---|
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.
Nova Healths medical professionals provide treatment for urgent care, primary care and physical therapy services throughout the Western US.
A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.
We never stop striving for a better future. A true passion for improving patient lives. Medical education - The surgeon is never alone.